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Aims The aim of this study was to evaluate the haemodynamic effects of serelaxin (30 mg/kg/day 20-h infusion and 4-h post-
infusion period) in patients with acute heart failure (AHF).
Methods
and results
This double-blind, multicentre study randomized 71 AHF patients with pulmonary capillary wedge pressure (PCWP)
≥18 mmHg, systolic blood pressure (BP) ≥115 mmHg, and estimated glomerular filtration rate ≥30 mL/min/1.73 m2
to serelaxin (n ¼ 34) or placebo (n ¼ 37) within 48 h of hospitalization. Co-primary endpoints were peak change
from baseline in PCWP and cardiac index (CI) during the first 8 h of infusion. Among 63 patients eligible for haemody-
namic analysis (serelaxin, n ¼ 32; placebo, n ¼ 31), those treated with serelaxin had a significantly higher decrease in
peak PCWP during the first 8 h of infusion (difference vs. placebo: 22.44 mmHg, P ¼ 0.004). Serelaxin showed no
significant effect on the peak change in CI vs. placebo. Among secondary haemodynamic endpoints, a highly significant
reduction in pulmonary artery pressure (PAP) was observed throughout the serelaxin infusion (largest difference in
mean PAP vs. placebo: 25.17 mmHg at 4 h, P , 0.0001). Right atrial pressure, systemic/pulmonary vascular resistance,
and systolic/diastolic BP decreased from baseline with serelaxin vs. placebo and treatment differences reached statistical
significance at some time points. Serelaxin administration improved renal function and decreased N-terminal pro-brain
natriuretic peptide levels vs. placebo. Treatment with serelaxin was well tolerated with no apparent safety concerns.
Conclusion The haemodynamic effects of serelaxin observed in the present study provide plausible mechanistic support for improve-
ment in signs and symptoms of congestion observed with this agent in AHF patients.
ClinicalTrials.gov identifier NCT01543854.
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Introduction
Acute heart failure (AHF) is a heterogeneous clinical syndrome with
worldwide increasing prevalence, poor outcomes, and very high
healthcare costs.1,2 Despite extensive research effort, there has
been no significant pharmacological advance in the management of
AHF patients with respect to mortality and dyspnoea relief for
several decades.1 Indeed, current treatment aimed at early clinical
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roningen user on 29 January 2020
stabilization and symptomatic improvement, namely loop diuretics
with inotropes and vasodilators, does not have supporting data on
long-term outcomes. This unmet need provides impetus to the
on-going search for novel therapies that would be able to meet
these therapeutic goals.
Serelaxin is a recombinant form of human relaxin-2, a naturally oc-
curring peptide hormone that, in women, mediates maternal systemic
haemodynamic and renal adaptations to an increase in intravascular
volume during pregnancy.3 Relaxin-2 exerts numerous haemodynam-
ic and renal effects in pregnant women, such as increase in arterial
compliance with concomitant fall in systemic vascular resistance
(SVR), and increase in renal blood flow, glomerular filtration rate,
and cardiac output (CO).4–6 Since all these effects of relaxin-2 can
be potentially beneficial for the treatment of AHF, clinical applicability
of its analogue (serelaxin) has been evaluated in this setting.7,8 In the
pilot Pre-RELAX-AHF phase II, dose-finding study, for example, treat-
mentwith serelaxin resulted inbeneficial effectsonbothdyspnoeaand
post-discharge clinical outcomes in AHF patients admitted to the
emergency room with evidence of congestion, normal-to-raised sys-
tolic blood pressure (BP), and mild-to-moderate renal dysfunction.7
These results were subsequently confirmed in RELAX-AHF, a larger
phase III study,whereearly treatmentwithserelaxinwaswell tolerated
and associated with significant dyspnoea relief and, among safety end-
points, a 37% reduction in 180-day mortality.8 An explanation of these
beneficial clinical outcomes isdesirable, and it has been postulated that
prevention of end-organ damage and early relief from congestion
resulting from serelaxin treatment may be associated with a reduction
in all-cause mortality.9 It is tempting to speculate that the favourable
haemodynamic effects, that serelaxin exerts in an early phase of
AHF, may translate into relief of congestion, symptomatic improve-
ment, and subsequent longer-term benefits. However, in the setting
of heart failure, haemodynamic effects of serelaxin have only been
characterized in a small group of patients with advanced, but stable
clinical conditions.5 Thus, we have designed a study to evaluate the
haemodynamic effects of serelaxin in patients with AHF at a dose
rate of 30 mg/kg/day, as was administered in the RELAX-AHF study.8
Methods
Study participants
Male and female patients 18 years of age and above hospitalized for AHF
who could be randomized within 48 h of presentation were eligible for
participation. Acute heart failure was defined as new onset or worsening
of signs and symptoms of heart failure requiring urgent therapy (e.g. dys-
pnoea at rest or on minimal exertion and pulmonary congestion at the
time of presentation), and patients were non-electively admitted/
required admission to hospital for AHF management. Patients were ini-
tially stabilized with furosemide, 40–120 mg/day i.v. (orother loop diure-
tics at equivalent dose) with no planned change in diuretic dose/use of i.v.
vasodilator from 4 h prior to treatment initiation till 8 h thereafter.
Central haemodynamic monitoring of the patients had to be initiated at
least 1 h before randomization with a mean pulmonary capillary wedge
pressure (PCWP) ≥18 mmHg.
The main exclusion criteria were systolic BP ,115 mmHg or esti-
mated GFR ,30 mL/min/1.73 m2 (calculated using the simplified Modi-
fication of Diet in Renal Disease equation); history of acute coronary
syndrome, major neurological event, or known significant valvular
disease or AHF due to significant arrhythmias; acute myocarditis; or
hypertrophic obstructive, restrictive, or constrictive cardiomyopathy;
recent i.v. contrast radiography, acute contrast-induced nephropathy,
or clinically significant hepatic impairment; planned treatment with i.v.
therapies including inotropic agents, vasopressors, levosimendan, nesiri-
tide, or analogues, or mechanical support (intra-aortic balloon pump,
endotracheal intubation, mechanical ventilation, or any ventricular-assist
device); current or planned organ transplant, ultrafiltration, haemofiltra-
tion, dialysis, or major surgery.
Study design
This was a randomized, double-blind, placebo-controlled, parallel-group,
multicentre study. The study was conducted in compliance with Good
Clinical Practice outlined in the principles of the Declaration of Helsinki,
and wasapprovedbyan ethics committee or institutional reviewboard of
each participating centre and regulatory authorities. It was registered
with ClinicalTrials.gov (NCT01543854). All participants provided written
informed consent.
The study consisted of a 2-day screening period, a baseline period and a
20-h i.v. infusion treatment period with study drugs followed by a 4-h
washout period. The study completion evaluation was done at 30 (+3)
days after the start of the treatment. Patients meeting the selection criteria
for enrolment during the screening period had a 7F Swan–Ganz Thermo-
dilution catheter inserted to assess baseline PCWP on Day 1 of the study
after stable haemodynamic measurements over at least 1 h. Baseline
PCWP was calculated as the mean of the last three measurements
taken at least 15 min apart immediately prior to randomization, which
were required to be stable (within 15% of each other). Cardiac output
measurements had to be stable (within 15% or no .0.5 L/min of each
other) and baseline CO was calculated as the mean of up to three assess-
ments in patients with sinus rhythm and five assessments in atrial fibrilla-
tion considering significant variability. Eligible patients were randomized
in a 1:1 ratio to serelaxin orplacebo, after baseline assessments were com-
pleted. Randomization numbers were generated (by the study sponsor)
using an automated and validated system to assign treatment arms,
which were concealed from patients and investigators. The placebo
used was a buffer solution with an appearance identical to serelaxin to
achieve blinding. Patients, investigator staff, and personnel performing
the assessments were blinded to the identity of the treatment.
Serelaxin or matching placebo was administered as a 30 mg/kg/day
infusion for 20 h (at a rateof 10 mL/h). If the patient’s systolic BPdecreased
by .40 mmHg from baseline, but was .90 mmHg in two consecutive
measurements 15 min apart, then the infusion rate was reduced to
half for the rest of the administration. If systolic BP was reduced to
,90 mmHg, infusion was terminated. Hypotension was reported as an
adverse event (AE) by the investigators. Use of rescue medication, includ-
ing i.v. vasodilators, to treat severe or serious conditions was allowed and
recorded.Furosemide40 mg(i.v. bolus)wasadministered4 hbefore the
start of the study drug infusion and repeated 8 h after the initiation of the
infusion and haemodynamic assessment, if clinically indicated. On the next
day furosemide, 40 mg i.v. was administered 4 h after the end of the study
drug infusion and haemodynamic assessment, if required. For patients re-
quiring furosemide 120 mg/day i.v., half the dose was advised to be given
at 12-h intervals as mentioned earlier. Per study protocol, all oral medica-
tions were planned to be administered in the morning on Day 1 and after
4 h of completion of infusion and haemodynamic assessments on Day 2.
Haemodynamic assessments were carried out at baseline and at 0.5, 2,
4, 6, 8, 20, 21, 22 and 24 h after initiation of the study drug infusion, which
covered the 20-h infusion period and the 4-h post-infusion (washout)
period. Cardiacoutput wasdetermined by the thermodilution technique.
Brachial systolic and diastolic BP and pulse rate were measured using the
A-PULSE CASProw device (HealthSTATS International, Singapore)
during haemodynamic assessments, and on Day 3 and Day 30 (follow-
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up). N-terminal pro-brain natriuretic peptide (NT-pro-BNP) levels were
analysed using commercially available kits (Roche Diagnostics GmbH
Mannheim, Germany) at baseline and at 8, 20, and 44 h after the study
treatment initiation.
Efficacy assessments
Co-primary endpoints were peak changes from baseline in PCWP and CI
during the first 8 h of infusion. Secondary haemodynamic endpoints
included right atrial pressure (RAP), systolic, diastolic and mean pulmon-
aryartery pressure (PAP), CO, SVR, pulmonary vascular resistance (PVR)
and systolic/diastolic BP evaluated during the 24-h period after infusion
initiation. Other endpoints included urine flow rate, urinary excretion
of creatinine, and creatinine clearance measured from urine collection
fractions over 24 h and cardio-renal biomarkers including NT-pro-BNP.
Safety monitoring
Safety assessments included monitoring of clinical signs and symptoms at
screening and signs throughout the treatment phase, physical examin-
ation, electrocardiogram, standard clinical laboratory evaluations
(haematology, blood chemistry, and urinalysis), and AE, and serious AE
(SAE) monitoring. All the patients were followed up to Day 30 (+3)
for safety assessments.
Statistical analysis
Assuming a standard deviation (SD) of 6 mmHg10,11 and the true drug
effect of a reduction of ≥4.2 mmHg, this study had at least 80% power
to detect a treatment difference from placebo in peak change from base-
line PCWP (co-primary endpoint) that is considered to be both statistic-
ally (two-sided P , 0.05) and clinically significant (estimated treatment
difference .3 mmHg) with a sample size of 64 patients (32 patients
per group). In addition, with reported SD of 0.5 L/min/m2 for CI10,11
and 32 patients per group, assuming the true drug effect of an increase
of≥0.35 L/min/m2, the study also had at least 80% power to detect a stat-
istically and clinically significant treatment difference (mean estimate
.0.25 L/min/m2) in peak change from baseline in CI (second co-primary
endpoint). Assuming a dropout rate of 10%, 35 patients per group
needed to be randomized in order to obtain 32 analysable patients.
The safety population consisted of all patients who received the study
drug infusion and had at least one post-baseline safety assessment. The
efficacy population consisted of all patients who received at least 8 h of
the study drug infusion, had at least one post-baseline assessment of a
primary haemodynamic variable and no major protocol deviations.
Peak change from baseline in PCWP and CI over 8 h of infusion was
assessed by analysis of covariance (ANCOVA) using treatment as classi-
fication factor and corresponding baseline value as covariate through the
SAS software (Version 9.3, Cary, NC, USA). Time-weighted average
change from baseline and change from baseline for each scheduled
time point were also analysed. Treatment difference in least squares
means (LSmeans) and theassociated two-sided 95%confidence intervals
as well as P-values were calculated. Secondary endpoints were analysed
similarly. For calculating time-weighted average change from baseline
using area under the effect curve, missing values at the end time point
of each interval were imputed using the last observation carried
forward method before applying the trapezoidal rule. For urine flow
rate, creatinine clearance, and NT-pro-BNP, data were log-transformed
before analysis. The post hoc ANCOVA test was carried out to confirm
results of the per-protocol analysis in the intention-to-treat data set
(including all the patients who received drug infusion), using the same
factors and covariates.
Results
Patient disposition and baseline
characteristics
Patient enrolment was started in March 2012 and completed in
January 2013. Out of a total of 120 patients screened, 71 patients
were randomized (serelaxin, n ¼ 34; placebo, n ¼ 37) from 17
sites in 6 countries (Russia, Germany, Poland, Argentina, Italy, and
The Netherlands). The remaining 49 patients did not meet eligibility
criteria and were screening failures. Demographic and baseline char-
acteristics were similar between serelaxin and placebo groups
(Table 1). Patient disposition is summarized in Figure 1. Overall, 71
patients received study drug (serelaxin, n ¼ 34; placebo, n ¼ 37)
and were included in the safety analysis; 63 patients (serelaxin, n ¼
32; placebo, n ¼ 31) were eligible for haemodynamic analysis. One
patient was excluded from the primary analysis in the serelaxin
group because 8 h of drug infusion was not completed. Another
serelaxin-treated patient and six placebo recipients were excluded
due to protocol deviations that can affect efficacy assessments, the
most common being use of furosemide during the initial 8 h of infu-
sion (serelaxin, n ¼ 1; placebo, n ¼ 5).
Effects of serelaxin on haemodynamic
parameters
Co-primary endpoints
Baseline mean (SD) PCWP was similar between treatment groups at
26.1 (5.9) mmHg in the serelaxin group and 26.5 (5.2) mmHg in the
placebo group. Patients treated with serelaxin had significantly
larger decrease in peak PCWP during the first 8 h of infusion when
compared with those who received placebo (P ¼ 0.004, Table 2).
Baseline mean (SD) CI was 2.4 (0.7) L/min/m2 in the serelaxin
group and 2.2 (0.6) L/min/m2 in the placebo group. There was no sig-
nificant effect of serelaxin 8-h infusion on peak change in CI vs.
placebo (P ¼ 0.79, Table 2).
Secondary endpoints
Compared with placebo, treatment with serelaxin resulted in a stat-
istically significant treatment difference in the time-weighted average
PCWP change from baseline over 0–8 h (P ¼ 0.0001) and over
8–20 h (P ¼ 0.03, Table 2). Effects on PCWP in the serelaxin group
were already apparent at 30 min, becoming statistically significant
after 2 h (Figure 2). Effect of serelaxin on PCWP was sustained till com-
pletionof thedrug infusion;however, therewasnosignificantdifference
compared with placebo at time points between 20 and 24 h (Figure 2)
and in the time-weighted average change from baseline over 20–24 h
(P ¼ 0.27, Table 2). Serelaxin leads to a small increase in CI that was
also noted in the placebo group during the entire 20-h infusion
period, and no significant treatment effect was observed (Table 2).
Serelaxin significantly lowered PAP (systolic and diastolic) with the
effect becoming evident and statistically significant already after the
first 30 min of infusion [for mean PAP at 30 min, treatment effect
as LS mean difference vs. placebo: 23.01 (95% confidence interval:
25.20, 20.81) mmHg, P ¼ 0.0072; largest treatment effect 25.17
(27.49, 22.86) mmHg occurred 4 h after the start of infusion, P ,
0.0001] (Table 2), sustained throughout the whole infusion period
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Table 1 Demographic data and baseline characteristics of randomized patients
Serelaxin (n 5 34) Placebo (n 5 37) Total (n 5 71)
Age (years) 66.6 (11.2) 70.4 (12.4) 68.6 (11.9)
Height (cm) 169.9 (7.8) 168.3 (9.4) 169.1 (8.6)
Weight (kg) 89.2 (20.2) 86.0 (21.1) 87.5 (20.6)
Sex: male; n (%) 27 (79.4) 26 (70.3) 53 (74.6)
Body mass index (kg/m2) 31.1 (7.6) 30.6 (9.0) 30.8 (8.3)
eGFR (mL/min/1.73 m2) 71.7 (23.7) 67.7 (24.1) 69.7 (23.8)
Baseline SBP (mmHg) 131.1 (14.7) 131.6 (17.1) 131.3 (15.9)
Baseline DBP (mmHg) 84.3 (10.7) 84.3 (13.0) 84.3 (11.9)
Time from AHF hospitalization to start of infusion (h) 27.9 (11.2) 30.0 (11.2) 29.0 (11.2)
Prior history of HF; n (%) 34 (100) 34 (91.9) 68 (95.8)
NYHA classificationa; n (%)
Class III 14 (41.2) 20 (54.1) 34 (47.9)
Class IV 20 (58.8) 17 (45.9) 37 (52.1)
Prior HF hospitalization; n (%) 25 (73.5) 33 (89.2) 58 (81.7)
Ejection fractionb (%) 34.5 (15.3) 32.5 (12.7) 33.4 (13.7)
Primary aetiology; n (%)
Ischaemic 16 (47.1) 20 (54.1) 36 (50.7)
Non-ischaemic 10 (29.4) 14 (37.8) 24 (33.8)
Alcoholic 1 (2.9) 0 (0) 1 (1.4)
Hypertensive 4 (11.8) 9 (24.3) 13 (18.3)
Infectious/viral cardiomyopathy 1 (2.9) 2 (5.4) 3 (4.2)
Other 4 (11.7) 9 (24.3) 13 (18.2)
Not known 2 (5.9) 0 (0) 2 (2.8)
Prior history of MI; n (%) 17 (50.0) 19 (51.4) 36 (50.7)
Concomitant disorders; n (%)
Hypertension 24 (70.6) 20 (54.1) 44 (62.0)
Atrial fibrillation 12 (35.3) 17 (45.9) 29 (40.8)
Diabetes 15 (44.1) 14 (37.8) 29 (40.8)
Chronic renal failure 6 (17.6) 6 (16.2) 12 (16.9)
Chronic obstructive pulmonary disease 7 (20.6) 5 (13.5) 12 (16.9)
Coronary artery disease 7 (20.6) 7 (18.9) 14 (19.7)
Prior medications (on admission); n (%)
Diuretics 34 (100) 37 (100) 71 (100)
ACE inhibitors 24 (70.6) 29 (78.4) 53 (74.6)
Angiotensin II antagonists 11 (32.4) 6 (16.2) 17 (23.9)
Beta-blocking agents 15 (44.1) 20 (54.1) 35 (49.3)
Alpha- and beta-blocking agents 20 (58.8) 16 (43.2) 36 (50.7)
Aldosterone antagonists 18 (52.9) 19 (51.4) 37 (52.1)
Digitalis glycosides 7 (20.6) 12 (32.4) 19 (26.8)
HMG CoA reductase inhibitors 20 (58.8) 21 (56.8) 41 (57.7)
Concomitant medications (on randomization); n (%)
Loop diuretics 34 (100.0) 36 (97.3) 70 (98.6)
Organic nitratesc 5 (14.7) 12 (32.4) 17 (23.9)
Heparin 20 (58.8) 15 (40.5) 35 (49.3)
Vitamin K antagonists 14 (41.2) 17 (45.9) 31 (43.7)
Baseline haemodynamic parametersd
PCWP (mmHg) 26.2 (5.9) 26.5 (5.2) —
CI (L/min/m2) 2.4 (0.7) 2.2 (0.6) —
Continued
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and remained significant until the end of the 24-h haemodynamic
evaluation (Table 2, Figure 2).
Changes in PAP and PCWP were mirrored by significant decrease
in PVR in patients treated with serelaxin. For the time-weighted
average PVR change from baseline, there were statistically significant
decreases over 0–8 h (P ¼ 0.0055) and 8–20 h (P ¼ 0.014, Table 2).
Peak mean RAP significantly decreased during 8 h of infusion in the
serelaxin group compared with placebo (P ¼ 0.0216). Systemic vas-
cular resistance decreased from baseline in the serelaxin group vs.
placebo, and treatment differences reached statistical significance
at some time points (Table 2 and Figure 2).
Slight decreases in systolic/diastolic BP with serelaxin were
observed already 30 min after the initiation of the infusion. Effects
on peripheral BP were sustained for 24 h after the infusion was
stopped in the serelaxin groupcomparedwith baseline. Indeed, treat-
ment differences were statistically significant for systolic BP at 20, 21,
and 27 h and for diastolic BP at 20, 21, 22, 24, 27, and 44 h (Figure 2).
During the infusionwith serelaxin, pulse rate increased toamaximum
of 78 (16) b.p.m. at 2 h [placebo: 79 (18) b.p.m.; mean (SD)] and
returned to baseline levels by the end of the 20-h infusion period.
It was 74 (12) b.p.m. in the serelaxin group and 79 (18) b.p.m. in
the placebo group at 44 h (Figure 2).
Results of haemodynamic parameters were similar in intention-
to-treat patient population on post hoc ANCOVA (see Supplemen-
tary material online, Table S1).
Effects of serelaxin on parameters of renal
function
The results on the effect of serelaxin on renal function are summar-
ized in Figure 3. Prior to the start of infusion (24 to 0 h), urine flow
rates were lower in the serelaxin group than in the placebo group
(geometric mean 168 vs. 215 mL/h). Urine flow rates decreased
from baseline in both treatment groups during the 20-h infusion
period. Over the entire 20-h infusion period, therewas 39% decrease
from baseline in urine flow rate in the serelaxin group compared with
a 59% decrease in the placebo group [ratio of LS mean ratio to base-
line 1.20 (0.98, 1.48), P ¼ 0.07 on post hoc ANCOVA].
Baseline (24 to 0 h) creatinine excretion rates were similar in the
serelaxin and placebo groups (geometric mean 0.47 and 0.53 mmol/h,
respectively). There was an 11% increase from baseline in urine cre-
atinineexcretion rate in the serelaxin groupanda21%decrease in the
placebo group during the 20-h infusion period [ratio of LS mean ratio
to baseline 1.25 (0.97, 1.61), P ¼ 0.09 on post hoc ANCOVA].
Baseline (24 to 0 h) creatinine clearance values were slightly
lower in the serelaxin group than in the placebo group (geometric
mean 84.2 vs. 96.1 mL/min). Over the entire 20-h infusion period
with serelaxin, there was a 20% increase from baseline in creatinine
clearance [geometric mean ratio 1.20 (0.90, 1.60)], whereas creatin-
ine clearance decreased from baseline by 24% in the placebo group
[geometric mean ratio 0.77 (0.58, 1.01)]. A post hoc ANCOVA con-
firmed a statistically significant treatment difference of 39% for 0–
20 h in creatinine clearance change from baseline [ratio of LS mean
ratio to baseline 1.39 (1.07, 1.81), P ¼ 0.0143].
Effect of serelaxin on natriuretic peptides
Baseline values of NT-pro-BNP were lower in the serelaxin group
compared with the placebo group (geometric mean 2702 and
3376 pg/mL, respectively). At the end of the 20-h infusion period,
there was a 13% decrease from baseline in NT-pro-BNP in the
serelaxin group and a 3% increase in the placebo group [ratio of LS
mean ratio to baseline 0.83 (0.69, 0.99), P ¼ 0.0366 on post hoc
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Continued
Serelaxin (n 5 34) Placebo (n 5 37) Total (n 5 71)
Systolic PAP (mmHg) 56.1 (13.0) 58.0 (13.8) —
Diastolic PAP (mmHg) 27.3 (6.2) 28.8 (6.9) —
Mean PAP (mmHg) 36.9 (7.9) 38.5 (8.1) —
RAP (mmHg) 12.7 (5.9) 12.3 (5.5) —
SVR (dynes × s/cm5) 1530 (462) 1720 (607) —
PVR (dynes × s/cm5) 210 (161) 243 (166) —
Data presented as mean (SD), unless otherwise specified.
eGFR, estimated glomerular filtration rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; AHF, acute heart failure; HF, heart failure; MI, myocardial infarction; NYHA,
New York Heart Association; ACE, angiotensin-converting enzyme; HMG CoA, 5-hydroxyl-3-methylglutaryl-coenzyme A; PCWP, pulmonary capillary wedge pressure; CI, cardiac
index; PAP, pulmonary arterial pressure; RAP, right atrial pressure; SVR, systemic vascular resistance; PVR, pulmonary vascular resistance.
aAt the time of screening, bserelaxin, n ¼ 22; placebo, n ¼ 30, coral or i.v., dserelaxin, n ¼ 32; placebo, n ¼ 31.
Figure 1 Patient disposition. *Between Day 3 and Day 30 for all
three patients.
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Table 2 Summary of changes from baseline in haemodynamic indices




Peak PCWP over 8 h 26.69 (0.59) 24.25 (0.60) 22.44 (24.10, 20.78) 0.0040
Time-weighted averagea
0–8 h 23.79 (0.50) 21.08 (0.51) 22.70 (24.10, 21.31) 0.0001
8–20 h 24.90 (0.73) 22.67 (0.74) 22.24 (24.28, 20.19) 0.0322
0–20 h 24.46 (0.59) 22.04 (0.60) 22.42 (24.08, 20.76) 0.0042
20–24 h 24.41 (0.83) 23.11 (0.85) 21.30 (23.63, 1.03) 0.27
CI (L/min/m2)
Peak CI over 8 h 0.32 (0.05) 0.30 (0.05) 0.02 (20.13, 0.16) 0.79
Time-weighted averagea
0–8 h 0.12 (0.04) 0.07 (0.04) 0.04 (20.07, 0.15) 0.48
8–20 h 0.05 (0.05) 0.07 (0.05) 20.02 (20.15, 0.12) 0.80
0–20 h 0.08 (0.04) 0.07 (0.04) 0.01 (20.11, 0.12) 0.92
20–24 h 0.08 (0.05) 0.03 (0.05) 0.05 (20.09, 0.20) 0.46
Systolic PAP (mmHg)
Peak systolic PAP over 8 h 210.77 (1.03) 24.59 (1.05) 26.19 (29.07, 23.30) ,0.0001
Time-weighted averagea
0–8 h 25.35 (0.93) 0.64 (0.94) 25.99 (28.59, 23.39) ,0.0001
8–20 h 25.87 (1.15) 20.12 (1.17) 25.74 (28.97, 22.52) 0.0005
0–20 h 25.66 (0.98) 0.18 (1.00) 25.84 (28.59, 23.09) ,0.0001
20–24 h 25.05 (1.28) 21.92 (1.30) 23.13 (26.71, 0.44) 0.09
Diastolic PAP (mmHg)
Peak diastolic PAP over 8 h 26.50 (0.70) 23.89 (0.71) 22.62 (24.58, 20.66) 0.0089
Time-weighted averagea
0–8 h 23.29 (0.59) 20.22 (0.60) 23.07 (24.73, 21.42) 0.0003
8–20 h 23.95 (0.80) 21.09 (0.81) 22.86 (25.10, 20.63) 0.0119
0–20 h 23.69 (0.64) 20.74 (0.65) 22.95 (24.74, 21.16) 0.0012
20–24 h 23.93 (0.86) 21.51 (0.88) 22.42 (24.84, 0.00) 0.05
Mean PAP (mmHg)
Peak mean PAP over 8 h 27.56 (0.72) 23.63 (0.74) 23.93 (25.96, 21.90) 0.0001
Time-weighted averagea
0–8 h 23.98 (0.65) 0.06 (0.66) 24.04 (25.86, 22.22) ,0.0001
8–20 h 24.56 (0.88) 20.80 (0.89) 23.76 (26.22, 21.29) 0.0028
0–20 h 24.32 (0.72) 20.45 (0.73) 23.87 (25.89, 21.85) 0.0002
20–24 h 24.29 (0.96) 21.67 (0.98) 22.62 (25.31, 0.07) 0.06
RAP (mmHg)
Peak mean RAP over 8 h 23.24 (0.36) 22.07 (0.36) 21.16 (22.16, 20.17) 0.0216
Time-weighted averagea
0–8 h 21.12 (0.36) 20.23 (0.36) 20.89 (21.89, 0.12) 0.08
8–20 h 21.12 (0.55) 20.62 (0.55) 20.49 (22.02, 1.03) 0.53
0–20 h 21.12 (0.45) 20.47 (0.45) 20.65 (21.89, 0.59) 0.31
20–24 h 21.26 (0.67) 21.45 (0.67) 0.19 (21.68, 2.06) 0.84
SVR (dynes × s/cm5)
Peak SVR over 8 h 2368.06 (45.92) 2284.62 (45.92) 283.44 (2211.72, 44.85) 0.20
Time-weighted averagea
0–8 h 2166.15 (44.73) 229.24 (44.73) 2136.91 (2261.89, 211.93) 0.0318
8–20 h 2158.82 (57.04) 227.20 (57.04) 2131.62 (2291.00, 27.76) 0.11
Continued
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ANCOVA].By44 h, therewasa33%decrease frombaseline in theser-
elaxin groupanda14%decrease in theplacebogroup [ratioofLSmean
ratio to baseline 0.75 (0.60–0.93), P ¼ 0.0101 on post hoc ANCOVA].
Adverse events
The drug infusions werewell tolerated (Table3). A total of 49 patients
(69%) experienced at least one AE during the study, with a slightly
lower proportion of patients in the serelaxin group (21 patients;
62%) than in the placebo group (28 patients; 76%). Adverse event
of particular interest (hypotension/BP decreased/syncope) was re-
ported by non-significantly more patients in the serelaxin group
(five patients; 15%) compared with the placebo group (three pat-
ients; 9%); however, the majority of events was of mild-to-moderate
severity. Serelaxin infusionwas stoppedprematurely in threepatients
as per the protocol-defined criteria of decrease in systolic BP. Eleven
patients experienced 11 SAEs during the study: three (9%) patients in
the serelaxin group and eight (22%) patients in the placebo group.
None of thesewas suspected to be related to study drug by the inves-
tigators, while fourevents were fatal (serelaxin: one acutemyocardial
infarction on Day 8 and one acute pulmonary oedema 21 h post-
dose; placebo: one spinal column injury on Day 22 and one pulmon-
ary oedema on Day 23).
Discussion
This is the first study specifically designed to evaluate the haemo-
dynamic effects of serelaxin, given as a 20-h infusion, in patients hos-
pitalized due to AHF. The major novel findings are that serelaxin
exerted rapid haemodynamic effects, characterized by a reduction
in PCWP and PAP with concomitant decrease in SVR and PVR.
Most of these changes were apparent early (being detectable
already after initial 30 min) and sustained throughout the entire infu-
sion period. No significant changes in CI were detected. Consistent
with earlier clinical studies, serelaxin therapy caused a slight decrease
in systolic/diastolic BP, without a change in pulse rate and any drug-
related serious tolerability concerns. Renal effects included
significantly increased creatinine clearance; and NT-pro-BNP levels
decreased with serelaxin infusion when compared with placebo.
Again, these findings are consistent with earlier observations from
the RELAX-AHF trial.8
Relaxin-2 is a naturally occurring peptide that possesses multiple
systemic and renal vasodilatory properties, for example, mediating
maternal adjustments to pregnancy.3 Importantly, numerous experi-
mental and clinical studies using relaxin-2 have confirmed these
effects, which form the background to believe that the physiological
effects of this hormone may be pharmacologically useful in modulat-
ing cardiovascular and renal function in the setting of heart failure.4– 6
Acute heart failure is a complex and heterogeneous clinical entity
with numerous underlying pathophysiological mechanisms, among
which vasoconstriction plays a central role.12 Constriction of the
venous and arterial beds has deleterious effects on the end-organs
and significantly contributes to the clinical progression of the
disease and symptoms in the setting of AHF. Thus, an augmented vas-
cular tone may become a target for treatment in selected AHF
patients. In fact, all the epidemiological data confirm that the majority
of patients admitted to the hospital due to AHF present with
normal-to-elevated systolic BP and has a clinical profile labelled as
‘acute vascular failure’ that can be characterized by the evidence of
vasoconstriction.13– 15 Therefore, it may well be expected that in
such a population, drugs with vasorelaxing properties to address
key underlying pathophysiological abnormalities would be prefer-
able. Importantly, although recently advocated, this ‘targeted ap-
proach’ has never been prospectively validated in clinical trials in
AHF. Relaxin-2, with its potent biological vasorelaxing properties,
seems to be an attractive therapeutic option.
Previous clinical experience with serelaxin in AHF is very encour-
aging. A phase II study, Pre-RELAX-AHF, demonstrated that in
patients with AHF, normal-to-elevated systolic BP and mild-to-
moderate renal dysfunction treatment with serelaxin significantly
improved dyspnoea and had favourable effects on post-discharge
clinical outcomes.7 These results wereconfirmed in the RELAX-AHF
phase III trial, which demonstrated that a 48-h infusion of serelaxin in
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Table 2 Continued
Haemodynamic parameter Serelaxin (n 5 32) Placebo (n 5 31) Treatment difference
(95% confidence interval)
P-value
0–20 h 2161.75 (48.44) 228.02 (48.44) 2133.74 (2269.09, 1.62) 0.05
20–24 h 2181.94 (67.36) 70.01 (67.36) 2251.95 (2440.15, 263.75) 0.0087
PVR (dynes × s/cm5)
Peak PVR over 8 h 277.73 (10.01) 252.69 (10.01) 225.04 (252.86, 2.78) 0.08
Time-weighted averagea
0–8 h 220.30 (9.91) 18.69 (9.91) 238.99 (266.53, 211.44) 0.0055
8–20 h 212.27 (12.28) 30.45 (12.28) 242.73 (276.85, 28.60) 0.0141
0–20 h 215.48 (10.08) 25.75 (10.08) 241.23 (269.25, 213.21) 0.0039
20–24 h 210.15 (16.20) 30.14 (16.20) 240.28 (285.31, 4.74) 0.08
Data represented as least squares mean (SE) change from baseline.
PCWP, pulmonary capillary wedge pressure; CI, cardiac index; PAP, pulmonary arterial pressure; RAP, right atrial pressure; SVR, systemic vascular resistance; PVR, pulmonary
vascular resistance.
aBased on area under the effect curve for the corresponding time interval.
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AHF patients with similar clinical characteristics resulted in improve-
ment of dyspnoea by visual analogue scale and other clinical signs/
symptoms of congestion; among secondary clinical and safety end-
points, a significant reduction in early worsening of heart failure
and a 37% reduction in cardiovascular and all-cause mortality
during the 180-day follow-up were observed.8 Several potential
explanations of these favourable short- and long-term effects of ser-
elaxin have been postulated, taking into account its numerous bio-
logical properties. It seems that early relief of congestion and
possible prevention of end-organ damage may be associated with re-
duction of the risk of clinical deterioration during hospital stay and
beneficial longer-term effects on mortality.9 One of the underlying
mechanisms may be related to the favourable haemodynamic
effects that serelaxin may exert in patients with AHF, as observed
in the present study, along with improvements in biomarkers of
end-organ damage.
Until now, haemodynamic effects of serelaxin have only been eval-
uated in a small, open-label study that recruited patients with
advanced, stable heart failure.5 In the present placebo-controlled
study, the vasorelaxant effects of serelaxin were shown with reduc-
tions in PCWP, mean PAP, and SVR without significant changes in CI
compared with placebo and standard therapy. However, direct com-
parisonbetween these two studies needs tobe rathercautious, as the
clinical responses in acute settings of heart failure may substantially
differ to that in patients with stable disease.
In the present study, serelaxin was characterized by decreases in
PCWP, PAP, RAP, SVR, and PVR that occurred early and were sus-
tained throughout thewhole infusion period. Serelaxindid not signifi-
cantly affect CI, as measured by the thermodilution method. Very
few patients required dose adjustment due to oligosymptomatic de-
creases in BP and despite the lower enrolment criterion for systolic
BP (≥115 mmHg before randomization) compared with the previ-
ous trials in AHF patients, the decreases in systolic/diastolic BP
were manageable and performed according to the same algorithm
as in RELAX-AHF. We believe that such careful monitoring of
changes in BP and appropriate adjustment of serelaxin therapy are
of particular relevance in order to avoid potential adverse events
related to hypotension. In fact, neither in this study nor in the RELAX-
AHF trial was any trend observed towards an increase in clinically
relevant adverse events related to hypotension.8 Importantly, changes
in PAP did not seem to be a simple consequence of a passive drop in
PCWP, as they were seen earlier and were more pronounced than
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .









Hypokalaemia 8 (23.5) 6 (16.2) 14 (19.7)
Haematuria 4 (11.8) 1 (2.7) 5 (7.0)
Hypotension 3 (8.8) 1 (2.7) 4 (5.6)
Constipation 1 (2.9) 3 (8.1) 4 (5.6)
Headache 0 (0.0) 3 (8.1) 3 (4.2)
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changes in PCWP. It may be hypothesized that serelaxin also exerts a
vasorelaxant effect on the pre-capillary pulmonary bed in patients
with AHF and normal-elevated BP, and further mechanistic studies
are warranted.
Renal changes during serelaxin infusion were characterized as a
modest increase in creatinine clearance without any marked effects
on serum levels of creatinine and urea (data not shown). Urine
flow decreased in both treatment groups, particularly during the
first 8 h of the infusion, but this seems to be related to our study
design with planned i.v. loop diuretic (bolus) administration at 4 h
before the initiation of infusion and after the first 8 h of the infusion.
Interestingly, at the end of the infusion there was a statistically signifi-
cant reduction in NT-pro-BNP in those receiving serelaxin. These
data confirm similar observations derived from the larger RELAX-
AHF trial.9
The interpretation of the favourable effects of any drug used in the
AHF setting in the context of potential beneficial consequences on
short- and long-term clinical outcomes remains controversial. Still,
a direct relationship between changes in haemodynamics and im-
provement in clinical signs and symptoms in the early phase of AHF
has not been confirmed. The results of studies with different drugs
remain inconclusive, because in several reports favourable effects
on haemodynamic indices were not directly related with better
symptomatic outcomes. Only recently, Solomonica et al.16 docu-
mented in a retrospective analysis that among haemodynamic
indices only acute changes in PCWP and PAP, but not SVR and CI,
predicted improvement in dyspnoea severity in patients with AHF.
Similarly, there are no haemodynamic indices for which changes
have been able to predict favourable longer-term outcomes.
However, the favourable haemodynamic ‘unloading’ profile of sere-
laxin demonstrated in this study may lead to more remarkable decon-
gestion, and the effects on the systemic and pulmonary vasculature
may translate into long-lasting improvement in end-organ perfusion
with less damage and possibly longer-term benefits found in the
RELAX-AHF study.8,9
Comparison of the present study results with reports of other
agents that have demonstrated haemodynamic improvements, such
as nesiritide, nitroglycerine (NTG), or ularitide would be of interest.
In the VMAC study, for example, nesiritide resulted in a significant re-
duction in the mean PCWP of 5.8 vs. 2 mmHg with placebo at 3 h.
Effects on CI were significantly different from placebo at 1 h with
nesiritide but not at 3 h. The comparator group treated with NTG
showed the mean PCWP reduction of 3.8 mmHg.10 In the SIRIUS II
study, ularitide was reported to significantly reduce PCWP at 6 h
(8.5 mmHg reduction with higher doses vs. 4 mmHg with
placebo) along with increase in CI (0.5–0.6 L/min/m2 with higher
doses vs. 0.3 L/min/m2 with placebo).11 Our results have shown
smaller changes from baseline in PCWP (peak effect of
26.69 mmHg during 8 h vs. 24.25 mmHg with placebo; maximum
effect of 25.03 mmHg vs. 21.5 mmHg with placebo at 8 h).
However, due to noteworthy differences in patient populations
studied, direct comparative clinical trials would be necessary to
draw robust conclusions. It is of note that despite demonstration of
haemodynamic improvements with these agents, there is no evi-
dence to support any improvements in long-term outcomes (for
examplewith nesiritide17) in contrast to what was observed with ser-
elaxin in the RELAX-AHF trial.8
Potential limitations of the study include the small sample size due
to the exploratory nature of the trial and use of per-protocol analysis,
which does not necessarily reflect the real-world setting. Patients
who received furosemide during the first 8 h of study drug infusion
were excluded from the per-protocol analysis. However, per-
protocol analysis was considered more appropriate for this study
with a view to reducing data variability by excluding subjects with
protocol deviations. To address potential limitations, an intention-
to-treat analysis (post hoc) was performed which entirely confirmed
the findings of the per-protocol analysis. Additionally, interpreting
the haemodynamic results, it needs to be remembered that changes
in PCWP were rather of modest magnitude, which indicates that they
are not the only mechanism underlying favourable results with sere-
laxin in other studies.7,8 Further, interpretation of safety assessments
is also limited by small sample size. These limitations aside, the study
results are considered robust and provide a comprehensive assess-
ment of the haemodynamic effects of serelaxin in patients with AHF.
Conclusions
Serelaxin was well tolerated with no apparent safety concerns and
exerted favourable haemodynamic effects on PCWP and PAP, but
did not significantly change CI, in patients with AHF and normal-
to-elevated systolic BP. These effects are consistent with the
changes in signs and symptoms of congestion observed with serelaxin
in previous clinical studies.
Supplementary material
Supplementary material is available at European Heart Journal online.
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